EUCTR2014-003055-60-AT进行中（未招募）1 期
Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, parallel group, multicenter study
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must fulfill the following criteria to be eligible for this study:
- •- 18 to <80 years of age at the time of informed consent
- •(The lower age limit may be higher if legally required in participating countries.)
- •- Male and female subjects with symptomatic PH and HF-PEF (group 2 / 2.2 of Dana Point classification and WHO class II to IV)
- •(Other groups of PH, especially HF-REF, PAH, CTEPH, must have been ruled out according to accepted diagnostic procedures and guidelines, see section 5.1.2 Exclusion criteria of the protocol)
- •PH-HF-PEF defined as:
- •- LVEF =50%, diagnosed by echocardiography or left heart catheterization (LHC)
- •within 30 days before randomization
- •- PAPmean =25 mmHg at rest, measured by RHC
- •- PAWP >15 mmHg at rest, measured by RHC
- •- Optimized therapy for hypertension
- •- The dose regimen of the background treatment must have been stable for >30 days before randomization. Diuretic therapy must have been stable for =1 week.
- •- RHC results for the definite diagnosis of PH not older than 12 weeks at Visit 1. RHC must have been performed in the participating center under standardized conditions (refer to the study-specific Swan-Ganz catheterization manual).
- •- CMRI must be performed at Visit 1 (baseline) or must not be older than 12 weeks with all parameters measured as listed in Section 7.3.3 of the protocol
- •- Women are eligible if not of childbearing potential, defined as:
- •- Postmenopausal women (i.e. last menstrual bleeding at least 2 years before randomization)
- •- Women with bilateral tubal ligation
- •- Women with bilateral ovariectomy
- •- Women with hysterectomy
- •or, if of childbearing potential, women are eligible if
- •- A serum pregnancy test is negative at the pre-study visit, and
- •- The woman uses a combination of condoms and a safe and highly effective contraception method (hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices) for the entire duration of the study
- •- Men enrolled in this study must agree to use adequate barrier birth control measures during the treatment period of the study and inform their sexual partners during the study period and three months beyond their study participation about the possibility of foetal impairment.
- •- Able to understand and follow instructions and to participate in the study for its entire duration
- •- Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •- PH in groups other than group 2.2 according to Dana Point classification
- •- Cardiac decompensation, with hospitalization or visit to the emergency department, =30 days before randomization
- •- Left heart disease because of to ischemic heart disease or dilated cardiomyopathy
- •- Resynchronization therapy at any time
- •- Need for intravenous (IV) diuretics =30 days before randomization
- •- Treatment with inotropes or IV vasodilators =30 days before randomization
- •- Pre-treatment with endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE5) inhibitors, or prostanoids =30 days before randomization, or with nitrates =7 days before randomization
- •- Subjects who medically require treatment with drugs that are not in line with the in- or exclusion criteria of this study or that are prohibited concomitant medications (see
- •section 6.9 of study protocol) for this study
- •- Bronchial asthma or chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) <60% of predicted
- •- Restrictive lung disease with total lung capacity (TLC) <60% of predicted
- •- Subjects on oxygen therapy
- •- Severe congenital abnormalities of the lung, thorax, or diaphragm
- •- Clinically relevant hepatic dysfunction shown by:
- •- Aspartate aminotransferase (AST) =3 times the upper limit of normal (ULN) or Child Pugh stage B and C in cirrhotic subjects
- •- Severe renal impairment (glomerular filtration rate [GFR] <30mL/min/1.73 m2 calculated by the Modification of Diet in Renal Disease [MDRD] formula)
- •- Uncontrolled arterial hypertension (SBP >180 mmHg or diastolic blood pressure [DBP] >110 mmHg)
- •- SBP <110 mmHg at baseline
- •- Myocardial disease, such as ischemic or dilative infiltrative myocardial disease (i.e. amyloidosis, hypertrophic cardiomyopathy)
- •- Severe aortic or mitral stenosis, or any such stenosis with indication for surgery
- •- Coronary artery disease with angina of Canadian Cardiovascular Society (CCS) class III or IV or requiring nitrates, unstable angina, or acute myocardial infarction <90 days before randomization
- •- Reperfusion procedure (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) <90 days before randomization, or <21 days in case of a negative stress test effect after PCI
- •- Stroke with persistent neurological deficit
- •- Subjects positive for human immunodeficiency virus (HIV)
- •- Resting HR while awake of <50 beats per minute (BPM) or >105 BPM (in case of atrial fibrillation >110 BPM)
- •- Participation in another clinical study <90 days before randomization
- •- Subjects with a medical disorder, condition, or history thereof that in the opinion of the investigator would impair the subject’s ability to participate or complete the 26-week study
- •- Subjects with underlying medical disorders with an anticipated life expectancy below
- •2 years because of a non-cardiac disease (e.g. active cancer disease with localized and / or metastasized tumor mass)
- •- Subjects with a history of multiple drug allergies
- •- Subjects with hypersensitivity to the investigational drug or any of the excipients
- •- Previous assignment to treatment during this study
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction in a randomized, double blind, placebo controlled, parallel group, multicenter studyPulmonary hypertension and heart failure with preserved ejectionfractionEUCTR2014-003055-60-DEMedical University of Vienna114
进行中（未招募）
不适用
A pharmacokinetic and pharmacodynamic study of recombinant human IGF-I (rhIGF-I) in three boys with ALS deficiency, and insulin sensitivity and bone density in patients and heterozygous first-degree relatives. - ALS deficiency: insulin resistance, bone strength & response to rhIGF1ALS (acid label subunit) deficiencyMedDRA version: 12.1Level: LLTClassification code 10056438Term: Growth Hormone DeficiencyEUCTR2010-019296-30-GBniversity Hospital Birmingham NHS Foundation Trust
进行中（未招募）
1 期
Combined growth hormone and IGF1 therapy in paediatric Crohn'd diseaseImpaired growth in Paediatric Crohn's diseaseMedDRA version: 14.1Level: LLTClassification code 10011398Term: Crohn'sSystem Organ Class: 100000004856EUCTR2010-022215-19-GBGreater Glasgow & Clyde NHS24
进行中（未招募）
不适用
Evaluation of the pharmacokinetic profile of Riluzole (XRP4274) and RPR112512 following multiple oral administrations of XRP4274 for 8 days in healthy Japanese and Caucasian male subjectsEUCTR2004-002390-23-DEAventis Pharma Ltd.
进行中（未招募）
不适用
Evaluation pharmacologique des antagonistes du récepteur P2Y12 à l'ADP chez le volontaire saiVolontaires sainsEUCTR2006-006695-38-FRCHU Toulouse